Robotic Endoluminal Surgery Market Report 2026

The robotic endoluminal surgery market size has grown rapidly in recent years. It will grow from $1.45 billion in 2025 to $1.71 billion in 2026 at a compound annual growth rate (CAGR) of 18.4%. The growth in the historic period can be attributed to increasing demand for minimally invasive procedures, rising adoption of endoscopic technologies, growing preference for shorter hospital stays, expanding use of robotic-assisted surgeries, increasing precision requirements for hard-to-reach anatomies.

The robotic endoluminal surgery market size is expected to see rapid growth in the next few years. It will grow to $3.33 billion in 2030 at a compound annual growth rate (CAGR) of 18.1%. The growth in the forecast period can be attributed to rising investment in surgical robotics research, growing integration of ai and machine learning in surgical platforms, increasing commercialization of flexible robotic systems, expanding clinical applications across gastrointestinal and vascular procedures, rising patient preference for faster recovery and reduced trauma. Major trends in the forecast period include technology advancements in flexible robotic endoscopes, innovations in capsule and micro-robotic devices, developments in ai-enabled navigation systems, research and developments in autonomous robotic surgery, advancements in real-time imaging and robotic visualization systems.

The growing adoption of minimally invasive surgeries is expected to drive the growth of the robotic endoluminal surgery market in the coming years. Minimally invasive surgeries are procedures performed through small incisions or a single entry point, reducing patient trauma, recovery time, and the risk of complications. Their adoption is increasing as hospitals and patients prioritize shorter recovery periods, less postoperative pain, lower complication risks, and minimal scarring compared with traditional open surgeries. Robotic endoluminal surgery facilitates these procedures by enabling precise navigation and manipulation within internal lumens, such as the gastrointestinal or respiratory tracts. It enhances patient outcomes by minimizing tissue trauma, shortening recovery times, and improving procedural accuracy. For example, in January 2025, Intuitive Surgical Inc., a US-based medical technology company, reported that worldwide da Vinci procedures - a type of minimally invasive robotic-assisted surgery - grew approximately 18% in the fourth quarter of 2024 compared with the same period in 2023. Full-year 2024 procedures increased about 17% compared with 2023, and the company projects worldwide da Vinci procedures to grow approximately 13% to 16% in 2025 compared with 2024. Consequently, the rising adoption of minimally invasive and single-port surgeries is fueling the expansion of the robotic endoluminal surgery market.

Major companies in the robotic endoluminal surgery market are focusing on developing advanced technologies, such as integrated artificial intelligence (AI) and real-time imaging systems, to enhance procedural accuracy, improve patient safety, and boost diagnostic efficiency. Integrated AI and advanced imaging systems combine machine learning with live procedural data to help physicians navigate complex anatomy and identify tissue targets with greater precision. For example, in October 2025, Intuitive Surgical Inc., a US-based medical technology company, received U.S. Food & Drug Administration (FDA) clearance for software enhancements for its Ion endoluminal system. The cleared innovations include improved 3D visualization of the lung airway tree and integration of AI-based imaging functionality, assisting in the detection of suspicious lung lesions during biopsy procedures. This integration is designed to provide more intuitive navigation and actionable information, supporting physician decision-making for precise tissue sampling and enhancing early lung cancer diagnosis, potentially improving patient outcomes.

In July 2025, Olympus Corporation, a Japan-based global medical technology company, partnered with Revival Healthcare Capital to establish Swan EndoSurgical, a new company focused on advancing robotic endoluminal surgery systems. Through this collaboration, Olympus and Revival Healthcare Capital aim to develop a novel robotic platform to transform gastrointestinal (GI) patient care by providing enhanced precision, flexibility, and control for endoluminal procedures. Revival Healthcare Capital is a US-based healthcare private equity and investment firm.

Major companies operating in the robotic endoluminal surgery market are Medtronic plc, Fujifilm Holdings Corporation, Intuitive Surgical Inc., Olympus Corporation, CMR Surgical Ltd., Noah Medical Inc., Distalmotion SA, Ronovo Surgical Inc., Stereotaxis Inc., Neocis Inc., MicroPort MedBot Co. Ltd., Virtual Incision Corporation, Asensus Surgical Inc., EndoQuest Robotics Inc., SS Innovations International Inc., Edge Medical Robotics, Moon Surgical, Robocath SAS, SurgEase Innovations, EndoTools Therapeutics SA, Microbot Medical Inc.

North America was the largest region in the robotic endoluminal surgery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the robotic endoluminal surgery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the robotic endoluminal surgery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are impacting the robotic endoluminal surgery market by increasing costs of imported robotic arms, flexible robotic instruments, imaging modules, control systems, and specialized surgical accessories. hospitals and ambulatory surgical centers in north america and europe are most affected due to reliance on imported advanced surgical robotics, while asia-pacific faces cost pressures in system manufacturing and distribution. these tariffs are increasing system acquisition costs and slowing adoption in mid-sized facilities. however, they are also encouraging domestic production, localized system integration, and regional innovation in cost-optimized robotic endoluminal platforms.

Robotic endoluminal surgery refers to the use of robot-assisted systems to perform minimally invasive procedures within hollow organs and natural body lumens, such as blood vessels, the gastrointestinal tract, and airways. These systems allow precise navigation, visualization, and manipulation of instruments within narrow and complex anatomical structures that are challenging to access with conventional surgery. By enhancing control, dexterity, and stability within internal passages, robotic endoluminal platforms improve surgical accuracy, minimize tissue trauma, and support faster patient recovery.

The primary product types of robotic endoluminal surgery systems are surgical systems, accessories and instruments, and services. Surgical systems are robotic platforms designed to perform minimally invasive procedures within hollow organs through natural orifices or small incisions. These systems are used in applications including gastrointestinal surgery, urological surgery, pulmonary surgery, gynecological surgery, and others, among end users such as hospitals, ambulatory surgical centers, specialty clinics, and others.

The robotic endoluminal surgery market includes revenues earned by entities through robotic-assisted minimally invasive endoluminal procedures, real-time surgical navigation and guidance, procedure planning and simulation, clinician training and support, intraoperative monitoring, and technical maintenance and system integration. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.